Regulatory review company Advarra has launched an enhancement of its Longboat platform that includes an online patient portal to improve collaboration between patients, sponsors and CROs.
Regulatory review company Advarra surpassed a milestone by expanding its gene therapy network to more than 1,000 research sites.
International health research network TriNetX has collaborated with nAdvarra to provide SiteIQ Plus to aid life sciences companies make ninformed decisions on clinical trial site selection.
COLUMBIA, Md., Oct. 25, 2021 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical research technology solutions, announced today the launch of Site IQ™ to enable faster study startup. The platform builds on Advarra's deep experience as the market leading IRB and leading provider of practice management solutions for clinical research, serving all of the top US research institutions, including the most renowned NCI-designated cancer centers, to deliver a unique, integrated set of site and principal investigator (PI) insights to enable smarter site selection. The Site IQ™ platform provides customized data analysis to help sponsors and CROs make informed decisions in their investigative site selection and feasibility processes.
Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical site-centric technologies, today announced the Advarra Gene Therapy Ready™ site network has grown to over 500 registered research sites, making Advarra the largest administrator of institutional biosafety committees (IBCs). Launched in January 2021, the Gene Therapy Ready network is a collective of clinical research sites prepared to conduct clinical trials involving genetically engineered vaccines, gene-modified cellular therapies, and gene therapies. Sites in the network demonstrate their readiness to address the challenges and opportunities presented by an accelerating gene therapy market that is expected to grow globally by 16.6 percent in the 2020-2027 period.
COLUMBIA, Md., March 9, 2021 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical site-centric technologies, today announced that it has acquired Bio-Optronics, maker of CCTrialSuite - which includes Clinical Conductor, the leading clinical trial management system (CTMS) for health systems and research sites, and an integrated suite of eClinical solutions. The acquisition, in combination with Advarra's existing suite of products and services, establishes Advarra as the site technology market leader with extensive reach, customer loyalty and the highest standards of customer support to the 50,000 investigators whose sites run on Advarra software.
COLUMBIA, Md., Jan. 19, 2021 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions and clinical site technologies, announces the Gene Therapy Ready™ site network, a comprehensive collective of clinical research sites ready to conduct clinical trials involving genetically engineered vaccines, gene-modified cellular therapies, and gene therapy research. The powerful aim of gene therapy is personalized medicine at scale with the goal of producing one-time treatments to patients. This initiative will address the challenges and opportunities presented by an accelerating gene therapy market that is expected to grow globally by 16.6 percent in the 2020-2027 period.
COLUMBIA, Md., Jan. 7, 2021 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions and clinical site technologies, is pleased to announce the acquisition of YourEncore, a leading provider of drug development and commercialization advisory and consulting services to the biopharmaceutical industry. YourEncore is powered by an extensive network of expert consultants who are experienced industry practitioners. Organized around three centers of excellence (quality, regulatory, and clinical), YourEncore provides outcome-oriented solutions designed to accelerate development, reduce risk, enhance compliance, and drive operational effectiveness and efficiencies.
The clinical site services provider continues its series of strategic company purchases by bringing the Irish trial technologies firm under its umbrella.
While traditional trial sites are under enormous pressure amid the Covid-19 pandemic, 3 pharma giants continue to back a leader in virtual clinical trials.